Froicu Eliza-Maria, Creangă-Murariu Ioana, Afrăsânie Vlad-Adrian, Gafton Bogdan, Alexa-Stratulat Teodora, Miron Lucian, Pușcașu Diana Maria, Poroch Vladimir, Bacoanu Gema, Radu Iulian, Marinca Mihai-Vasile
Department of Oncology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115, Iasi, Romania.
2nd Internal Medicine Department, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115, Iasi, Romania.
Curr Oncol Rep. 2025 Jun 17. doi: 10.1007/s11912-025-01698-8.
Artificial Intelligence (AI) integration in oncology is transforming therapeutic decision-making by providing clinical decision support. AI may improve treatment precision, but it raises ethical, legal, and informed consent issues. This review examines these paramount AI implementation issues in cancer care. This systematic review followed the PRISMA 2020 guidelines and was prospectively registered in the PROSPERO (CRD420251046482) database. A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane CENTRAL Library to identify studies published between January 2015 and May 2025. AI-supported oncology therapeutic decision-making studies with ethical, legal, or informed consent implications were eligible.
Fifteen studies met the inclusion criteria. AI applications were found to support treatment recommendations, personalize drug dosing, and improve adherence and patient management. Despite these benefits, the review highlighted key concerns, including algorithmic transparency, unclear accountability in AI-guided decisions, data privacy, and gaps in patient understanding of AI's role in their care. AI has the potential to enhance oncological care, but ethical and legal issues must be addressed for safe and equitable implementation. Emphasis should be placed on developing robust informed consent models, mitigating algorithmic bias, and establishing clear legal accountability. Future research must establish ethical frameworks and regulatory mechanisms to protect patient autonomy and responsibly integrate AI into oncology.
人工智能（AI）在肿瘤学中的整合通过提供临床决策支持正在改变治疗决策。人工智能可能会提高治疗精度，但它引发了伦理、法律和知情同意方面的问题。本综述探讨了癌症护理中这些至关重要的人工智能实施问题。本系统综述遵循PRISMA 2020指南，并已在PROSPERO（CRD420251046482）数据库中进行了前瞻性注册。在PubMed、Embase和Cochrane CENTRAL图书馆进行了全面的文献检索，以识别2015年1月至2025年5月期间发表的研究。涉及伦理、法律或知情同意问题的人工智能支持的肿瘤治疗决策研究符合纳入标准。
15项研究符合纳入标准。发现人工智能应用可支持治疗建议、个性化药物剂量，并改善依从性和患者管理。尽管有这些好处，但综述强调了关键问题，包括算法透明度、人工智能指导决策中不明确的问责制、数据隐私以及患者对人工智能在其护理中作用的理解差距。人工智能有增强肿瘤护理的潜力，但为了安全和公平地实施，必须解决伦理和法律问题。应强调制定强有力的知情同意模式、减轻算法偏差以及建立明确的法律问责制。未来的研究必须建立伦理框架和监管机制，以保护患者自主权并将人工智能负责任地整合到肿瘤学中。
